Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrahepatic cholangiocarcinoma: the equity gap in one of the most lethal cancers.

Journal of gastrointestinal oncology·2026
Same author

Racial and Sex Disparities in Patients With Takotsubo Cardiomyopathy With Inflammatory Bowel Disease.

Heart, lung & circulation·2026
Same author

Correction: Chen et al. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> 2024, <i>14</i>, 1030.

Diagnostics (Basel, Switzerland)·2025
Same author

Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma.

Cancer·2025
Same author

Evans Syndrome: Analysis of 1255 Adult Cases in US Hospitals, Revealing Demographics, Associations, and Outcomes.

International journal of hematology-oncology and stem cell research·2025
Same author

At the End of Life: The Impact and Disparities of Palliative Care Utilization Among Deceased Gastric Cancer Patients in US Hospitals.

Journal of racial and ethnic health disparities·2025

Related Experiment Video

Updated: Jul 12, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K

Metaxalone-induced Immune Hemolytic Anemia.

Afoma Onyechi1, Jessica Ohemeng-Dapaah1, Rushin Patel1

  • 1Department of Internal Medicine, SSM St. Mary's Hospital, St. Louis, MO, USA.

Journal of Community Hospital Internal Medicine Perspectives
|October 23, 2023
PubMed
Summary
This summary is machine-generated.

Drug-induced immune hemolytic anemia (DIIHA) is a rare anemia type. Metaxalone, a muscle relaxant, can cause DIIHA, presenting with jaundice and orange urine, which resolves with treatment.

Keywords:
Drug induced immune hemolytic anemiaHemolysisMetaxalone

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.6K
Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

82.1K

Related Experiment Videos

Last Updated: Jul 12, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.6K
Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

82.1K

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Drug-induced immune hemolytic anemia (DIIHA) is an uncommon but serious adverse drug reaction.
  • While beta-lactam antibiotics are frequently implicated, a wide range of medications can trigger DIIHA.
  • Accurate diagnosis of DIIHA can be challenging, often requiring a high index of suspicion.

Observation:

  • A patient developed jaundice and orange urine after initiating metaxalone for a lumbosacral sprain.
  • Clinical presentation suggested a warm hemolytic anemia.
  • These symptoms significantly improved upon metaxalone withdrawal.

Findings:

  • Metaxalone, a skeletal muscle relaxant, was identified as the likely causative agent for DIIHA.
  • Laboratory findings confirmed warm hemolytic anemia.
  • Discontinuation of metaxalone led to remarkable symptom resolution.

Implications:

  • This case highlights metaxalone as a potential cause of DIIHA, expanding the list of implicated drugs.
  • Early recognition and drug withdrawal are crucial for managing DIIHA.
  • Combination therapy with glucocorticoids and rituximab may be effective in treating severe DIIHA cases.